BELLUS Health Inc. (TSE:BLU) Director Joseph Rus Sells 35,643 Shares of Stock

BELLUS Health Inc. (TSE:BLUGet Rating) Director Joseph Rus sold 35,643 shares of BELLUS Health stock in a transaction dated Friday, November 18th. The shares were sold at an average price of C$12.14, for a total value of C$432,559.88.

BELLUS Health Trading Down 0.6 %

TSE:BLU opened at C$12.16 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 11.62 and a current ratio of 12.16. The firm has a market cap of C$1.53 billion and a price-to-earnings ratio of -11.58. BELLUS Health Inc. has a 52 week low of C$6.30 and a 52 week high of C$16.24. The firm has a 50-day moving average price of C$13.19 and a two-hundred day moving average price of C$12.64.

Wall Street Analyst Weigh In

Separately, Evercore ISI restated a “buy” rating and set a C$24.00 price objective on shares of BELLUS Health in a report on Tuesday, November 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of C$17.40.

About BELLUS Health

(Get Rating)

BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.

Featured Stories

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.